Results for tag: "Tagrisso"

Tagrisso (osimertinib) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is used to treat tumors with certain mutations in the EGFR gene. Tagrisso is approved for the treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. It is also approved for the treatment of NSCLC with EGFR T790M mutation as detected by an FDA-approved test. Tagrisso is used as a first-line treatment for metastatic NSCLC with EGFR mutations and as a second-line treatment for NSCLC with EGFR T790M mutation. Tagrisso is marketed by AstraZeneca and is available in the United States, Europe, and other countries. Other companies in the market include Pfizer, Merck, Bristol-Myers Squibb, and Roche. Show Less Read more